NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives $11.67 Consensus PT from Analysts

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $11.6667.

NMTC has been the topic of a number of recent analyst reports. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. JonesTrading initiated coverage on NeuroOne Medical Technologies in a research report on Monday, March 2nd. They issued a “buy” rating and a $9.00 price target on the stock. Zacks Research cut NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. LADENBURG THALM/SH SH raised their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings cut NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NMTC. Legato Capital Management LLC bought a new position in NeuroOne Medical Technologies in the fourth quarter valued at about $34,000. Squarepoint Ops LLC bought a new position in NeuroOne Medical Technologies in the fourth quarter valued at about $36,000. Susquehanna International Group LLP bought a new position in NeuroOne Medical Technologies in the third quarter valued at about $47,000. XTX Topco Ltd bought a new position in NeuroOne Medical Technologies in the second quarter valued at about $51,000. Finally, Goldman Sachs Group Inc. bought a new position in NeuroOne Medical Technologies in the first quarter valued at about $84,000. Institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ NMTC opened at $3.25 on Wednesday. NeuroOne Medical Technologies has a 52 week low of $3.11 and a 52 week high of $6.96. The stock has a market capitalization of $28.02 million, a P/E ratio of -3.82 and a beta of 0.51. The stock’s fifty day moving average is $4.11 and its 200 day moving average is $4.45.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $2.58 million. Equities research analysts forecast that NeuroOne Medical Technologies will post -0.35 earnings per share for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.